Researcher from the 3B’s Research Group, based at Avepark, develops innovative device for colorectal cancer diagnosis

Miguel Oliveira, a researcher at the 3B’s Research Group – Institute of Biomaterials, Biodegradables and Biomimetics, headquartered at Avepark, is leading the development of a new diagnostic device for colorectal cancer, one of the deadliest cancers in Portugal and the second most common among people under 50 years old. 

In the last ten years, the number of cases in this age group has doubled, and current diagnostic methods have proven insufficient to effectively address this reality. With the goal of providing a more accessible, effective, and less invasive solution, Miguel Oliveira’s team is developing a microfluidics-based device that analyzes blood samples to detect biological markers associated with the disease, at an early stage or even before its onset. 

Beyond early diagnosis, the device will also be able, in advanced stages of the disease, to isolate circulating tumor cells and create personalized disease models in the lab. This will enable predicting how the patient’s body will respond to different treatments, helping clinicians design more effective and personalized therapies. 

To learn more, listen to episode 2042 of the program 90 Segundos de Ciência by Antena 1 and Ciência Viva, where Miguel Oliveira explains this innovative project.